http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-11201903938X-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70ebe392b4988c5479996055ae123c27 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 |
| filingDate | 2017-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42aef0f244f051be7eca62fff516efa6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5161c47ea87dfc88101761d04df7a2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12e70413cdc360fdfdb21c67a7f94054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_295a27be289cef9dae018985af486ac1 |
| publicationDate | 2019-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | SG-11201903938X-A |
| titleOfInvention | Acylated glp-1/glp-2 dual agonists |
| abstract | WO 18/ 10 45 6 1 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 June 2018 (14.06.2018) WIP0 1 PCT 0111111010 0111 °nolo olonmElum limo oimIE (10) International Publication Number WO 2018/104561 Al (51) International Patent Classification: C07K 14/605 (2006.01) A61K 38/26 (2006.01) (21) International Application Number: PCT/EP2017/082290 (22) International Filing Date: 11 December 2017 (11.12.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA201600757 09 December 2016 (09.12.2016) DK (71) Applicant: ZEALAND PHARMA A/S [DK/DK]; Smede- land 36, DK-2600 Glostrup (DK). (72) Inventors: DUE LARSEN, Bjarne; Rorholm 12, DK-4000 Roskilde (DK). GRIFFIN, Jonathan; Bomvevsvagen 12, SE-22651 Lund (SE). GIEHM, Lise; Radmand Steins All& 29, 4th, DK-2000 Frederiksberg (DK). EDWARDS, Alistair Vincent Gordon; Vilhelm Buhls Gade 21, DK-2300 Copenhagen S (DK). (74) Agent: FORREST, Graham et al.; Mewburn Ellis LLP, City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: ACYLATED GLP-1/GLP-2 DUAL AGONISTS (57) : The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds fmd use, inter alia, in the prophylaxis or treatment of intestinal damage and dys- function, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction. |
| priorityDate | 2016-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.